Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Akebia to host conference call on August 25, 2023 at 9:00 a.m. ET Expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023 Reports Auryxia® (ferric citrate) net product revenue of $42.2 million for Q2 2023 and reaffirms 2023 net…
Comments Off on Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights